ReviewJournal of clinical medicine2020
Current and Future Trends in Molecular Biomarkers for Diagnostic, Prognostic, and Predictive Purposes in Non-Melanoma Skin Cancer.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HCHS-Net: A Multimodal Handcrafted Feature and Metadata Framework for Interpretable Skin Lesion Classification.Biomimetics (Basel, Switzerland) · 2026Article
- MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.Diagnostics (Basel, Switzerland) · 2025Review
- Lipid-based nanocarriers in combination chemotherapy: a promising strategy for advanced skin cancer management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- AI-assisted identification of nonmelanoma skin cancer structures based on combined line-field confocal optical coherence tomography and confocal Raman microspectroscopy.Journal of biomedical optics · 2025Article
- Emerging Technologies for Timely Point-of-Care Diagnostics of Skin Cancer.Global challenges (Hoboken, NJ) · 2025Review
- Leveraging Microorganisms to Combat Skin Cancer.Microorganisms · 2025Review
- Towards unbiased skin cancer classification using deep feature fusion.BMC medical informatics and decision making · 2025Article
- Emerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies.Medical sciences (Basel, Switzerland) · 2024Review
- Article
- Methylation‑sensitive restriction enzyme‑droplet digital PCR assay for the one‑step highly sensitive analysis of DNA methylation hotspots.International journal of molecular medicine · 2024Article
- Review
- SkinNet-INIO: Multiclass Skin Lesion Localization and Classification Using Fusion-Assisted Deep Neural Networks and Improved Nature-Inspired Optimization Algorithm.Diagnostics (Basel, Switzerland) · 2023Article
- Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers.Molecular biology reports · 2023Article
- Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023Review
- The Role of miRNA-221 and miRNA-34a in Non-Melanoma Skin Cancer of the Head and Neck Region.Genes · 2023Article
- Where Microneedle Meets Biomarkers: Futuristic Application for Diagnosing and Monitoring Localized External Organ Diseases.Advanced healthcare materials · 2023Review
- Defining the Profile of Patients with Primary Merkel Cell Carcinoma in Central Italy: A Retrospective Analysis.Cancers · 2022Article
- Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.International journal of molecular sciences · 2022Review
- An Efficient Deep Learning-Based Skin Cancer Classifier for an Imbalanced Dataset.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer represents the most common type of cancer among Caucasians and presents in two main forms: melanoma and non-melanoma skin cancer (NMSC). NMSC is an umbrella term, under which basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and Merkel cell carcinoma (MCC) are found along with the pre-neoplastic lesions, Bowen disease (BD) and actinic keratosis (AK). Due to the mild nature of the majority of NMSC cases, research regarding their biology has attracted much less attention. Nonetheless, NMSC can bear unfavorable characteristics for the patient, such as invasiveness, local recurrence and distant metastases. In addition, late diagnosis is relatively common for a number of cases of NMSC due to the inability to recognize such cases. Recognizing the need for clinically and economically efficient modes of diagnosis, staging, and prognosis, the present review discusses the main etiological and pathological features of NMSC as well as the new and promising molecular biomarkers available including telomere length (TL), telomerase activity (TA), CpG island methylation (CIM), histone methylation and acetylation, microRNAs (miRNAs), and micronuclei frequency (MNf). The evaluation of all these aspects is important for the correct management of NMSC; therefore, the current review aims to assist future studies interested in exploring the diagnostic and prognostic potential of molecular biomarkers for these entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.